Viewing nowZenisiga 10mg (Dapagliflozin Anhydrous Mixture)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
AlboGen Korea Co., Ltd.

MFDS item code 202005355 · Approved 2020.07.23 · Insurance code 652606850
Treatment of type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure
This medication helps control blood sugar in patients with type 2 diabetes and reduces the risk of death and hospitalization due to heart failure in patients with chronic heart failure. It is also used to lower risks associated with declining kidney function in patients with chronic kidney disease. It is particularly beneficial for patients with type 2 diabetes who have cardiovascular disease or risk factors. It is administered in conjunction with standard treatment for chronic heart failure and chronic kidney disease. This medication improves the patient's condition and effectively supports health management.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received antidiabetic drug therapy, the recommended initial dose of this medicine when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiating this medicine in patients with chronic heart failure and chronic kidney disease is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients who are allergic to the active ingredient or excipients. Do not administer to patients with type 1 diabetes or diabetic ketoacidosis. Contains anhydrous lactose and should not be used in patients with genetic conditions such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. Should also not be given to patients undergoing dialysis. Administer cautiously in patients with reduced fluid volume or renal dysfunction, and monitor closely for changes in blood pressure or renal function. Especially in elderly patients, those with impaired renal function, or patients on diuretics, there is an increased risk of hypotension. Contains Yellow No. 4 and Yellow No. 5 dyes, so caution is advised for patients allergic to these components. The most common side effect reported in clinical trials and post-marketing is genital infections, which may occur more frequently in females. Symptoms of hypoglycemia may occur more frequently when used in conjunction with insulin or sulfonylureas, so caution is needed. Symptoms of dehydration or hypotension due to reduced fluid volume may develop, so medical consultation should be sought immediately if these symptoms arise. Diabetic ketoacidosis may rarely occur; if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing appear, immediate examination is required. The risk of urinary tract infections and pyelonephritis may increase; any associated symptoms should be promptly treated. Renal function may decline, so regular kidney function tests are necessary. Severe infections such as perineal necrosis have been reported rarely; if there is pain or swelling around the perineum or fever, inform healthcare professionals immediately. Use is not recommended during pregnancy, and nursing mothers should avoid taking this medication. The safety and efficacy in children have not been established. In cases of overdose, there is no specific antidote; appropriate treatment based on symptoms should be administered. When taking this medication, it may be necessary to adjust the doses of insulin or sulfonylureas to reduce the risk of hypoglycemia. It is important to regularly check fluid status, blood pressure, and renal function during treatment with this medication. Keep out of reach of children and store in the original container to maintain quality.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, fluid volume depletion, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, lumbar pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar pruritus, genital pruritus, elevated hematocrit, decreased creatinine clearance at the beginning of treatment, dyslipidemia, elevated blood creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, chest pain, chest discomfort, fatigue, edema, foreign body sensation, facial swelling, facial pain, warmth, flu-like symptoms, breast mass, erectile dysfunction, benign prostatic hyperplasia, breast pain, genital rash, menorrhagia, genital edema, uterine bleeding, vaginal bleeding, discomfort of the vulva, menstrual irregularities, hair loss, dermatitis, dry skin, allergic dermatitis, contact dermatitis, diabetic foot ulcer, excessive sweating dermatitis, nummular eczema, eczema, hyperkeratosis, nail pigmentation, skin lesions, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, shortness of breath, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus, vaginal discharge, headache, sensory loss, paresthesia, nasopharyngitis, upper respiratory infection, asthenia, hunger, vaginal discharge, itching
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture, and keep it at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness over time.
Yellow, biconvex rhomboid film-coated tablets
28 tablets/box [(14 tablets/PTP X 2)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
AlboGen Korea Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.